Evidence map›Paper›PMID 39688742›Full record

ArticleInternational journal of clinical oncology2025

Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

Tokiyoshi Tanegashima, Masaki Shiota, Naoki Terada, Toshihiro Saito, Akira Yokomizo, Naoki Kohei, Takayuki Goto, Sadafumi Kawamura, Yasuhiro Hashimoto, Atsushi Takahashi and 25 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Tokiyoshi TanegashimaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. shiota.masaki.101@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-3306-4858
Naoki TeradaDepartment of Urology, Miyazaki University, Miyazaki, Japan.
Toshihiro SaitoDepartment of Urology, Niigata Cancer Center Hospital, Niigata, Japan.
Akira YokomizoDepartment of Urology, Harasanshin Hospital, Fukuoka, Japan.
Naoki KoheiDepartment of Urology, Shizuoka General Hospital, Shizuoka, Japan.
Takayuki GotoDepartment of Urology, Kyoto University, Kyoto, Japan.
Sadafumi KawamuraDepartment of Urology, Miyagi Cancer Center, Natori, Japan.
Yasuhiro HashimotoDepartment of Urology, Hirosaki University, Hirosaki, Japan.
Atsushi TakahashiDepartment of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan.
Takahiro KimuraDepartment of Urology, Jikei University, Tokyo, Japan.
Ken-Ichi TabataDepartment of Urology, Kitasato University, Sagamihara, Japan.
Ryotaro TomidaDepartment of Urology, Shikoku Cancer Center, Matsuyama, Japan.
Kohei HashimotoDepartment of Urology, Sapporo Medical University, Sapporo, Japan.
Toshihiko SakuraiDepartment of Urology, Yamagata University, Yamagata, Japan.
Toru ShimazuiDepartment of Urology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, Japan.
Shinichi SakamotoDepartment of Urology, Chiba University, Chiba, Japan.
Manabu KamiyamaDepartment of Urology, University of Yamanashi Hospital, Chuo, Japan.
Nobumichi TanakaDepartment of Urology, and Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Japan.
Koji MitsuzukaDepartment of Urology, Tohoku University, Sendai, Japan.
Takuma KatoDepartment of Urology, Kagawa University, Kagawa, Japan.
Shintaro NaritaDepartment of Urology, Akita University, Akita, Japan.
Hiroaki YasumotoDepartment of Urology, Shimane University, Izumo, Japan.
Shogo TeraokaDepartment of Urology, Tottori University, Yonago, Japan.
Masashi KatoDepartment of Urology, Nagoya University, Nagoya, Japan.
Takahiro OsawaDepartment of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan.
Yoshiyuki NagumoDepartment of Urology, University of Tsukuba Hospital, Tsukuba, Japan.
Hiroaki MatsumotoDepartment of Urology, Yamaguchi University, Ube, Japan.
Hideki EnokidaDepartment of Urology, Kagoshima University, Kagoshima, Japan.
Takayuki SugiyamaDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kentaro KuroiwaDepartment of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Hiroshi KitamuraDepartment of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan.
Toshiyuki KamotoDepartment of Urology, Miyazaki University, Miyazaki, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Japanese Urological Oncology Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Japan, since 2014, new treatments such as androgen receptor signaling inhibitors and cabazitaxel have become applicable for metastatic castration-resistant prostate cancer (mCRPC), leading to dramatic changes in treatment options.

objectiveThis study aims to evaluate the impact of recent advancements in treatment options on the overall survival (OS) of patients diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC) in Japan.

methodsA retrospective analysis was conducted on 2450 Japanese men diagnosed with de novo mCSPC between 2008 and 2018. Patients were stratified into two groups based on the period of diagnosis: an earlier period (2008-2013) and a later period (2014-2018). OS was compared between earlier and later periods using Kaplan-Meier analysis in total and propensity score matched subpopulation as well as risk-stratified subgroups.

resultsPatients diagnosed in the later period exhibited significantly improved OS compared to those diagnosed in the earlier period. The risk score, calculated based on ISUP grade group, LDH levels, and ALP levels, was a poor prognostic factor. In the later period, compared to the earlier period, there was no improvement in OS in the favorable-risk group, but a significant improvement was observed in the poor-risk group.

conclusionIt was suggested that the introduction of novel androgen receptor signaling inhibitors and chemotherapy treatment regimens since 2014 has led to improved survival outcomes for patients with de novo mCSPC, particularly those with poor-risk profiles. The findings highlight the impact of recent advancements in treatment on the prognosis of patients with metastatic prostate cancer in Japan.

Indexed as

Prostatic Neoplasms, Castration-ResistantAgedAged, 80 and overAndrogen Receptor AntagonistsHumansJapanKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisPrognosisRetrospective StudiesTaxoidsAndrogen Receptor AntagonistscabazitaxelTaxoidsDe novo mCSPCJapanOverall survivalPropensity score matchingProstate cancerRisk factors

Identifiers

PMID39688742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.